Talk:Sepiapterin

"Sepiapterin is a substrate of sepiapterin reductase"
The sole text in this article is "Sepiapterin is a substrate of sepiapterin reductase."

This article has no sources at all. I'd propose deletion, but people in the medicinal chemistry community are looking at sepiapterin as useful in reducing the effects of aging in humans, along with rapamycin and metformin.

Sepiapterin's interesting biochemistry satisfies WP:GNG. It's a prodrug for tetrahydrobiopterin, which is depleted during adulthood. As the cells' levels of tetrahydrobiopterin fall, incidence of atherosclerosis and Type 2 diabetes increases, so that sepiapterin could reasonably be expected to repair the endothelial damage responsible for those two disease processes of old age and extend the healthy life span of those who take it.

If anyone else has better sources than the ones I'll be placing in the article soon, please mention them here. --loupgarous (talk) 18:24, 25 October 2019 (UTC)


 * So far I've expanded the article with reference to sepiapterin's conversion via salvage pathway to tetrahydrobiopterin, the implications for treatment of tetrahydrobiopterin deficiency with sepiapterin, and studies I've found documenting human and animal studies of sepiapterin's effects (cited as references in our article). Any assistance in reviewing the article, suggestions for improvement, additional sources I have not yet cited would be warmly welcomed.


 * Also, asking experienced editors if we can take the "stub" tag off now. --loupgarous (talk) 18:12, 7 November 2019 (UTC)


 * This is a month after the first time I asked about taking the "stub" tag off of our article. I'm not anxious to do that, hoping that someone who's more knowledgeable about sepiapterin and its possible uses as a lead compound in drug development will help out with more content and/or reliable sources.  Help! loupgarous (talk) 16:02, 3 December 2019 (UTC)